This course provides an in-depth exploration of cardiometabolic conditions, focusing on the latest advancements in obesity treatments and their cardiac implications. Learners will gain a clear understanding of pharmacokinetics for novel and traditional weight loss therapies, including SGLT2 inhibitors and GLP-1 agonists, and learn how to address barriers to medication access. Enhance your clinical practice by mastering the tools to manage complex cases and optimize care for patients with obesity and Type 2 diabetes.
Learning Objectives
- Describe the epidemiology, pathophysiology and history of cardiometabolic conditions
- Compare pharmacokinetics of novel and traditional obesity therapeutics which includes patients with Type 2 diabetes (SGLT2is, GLP1s and GIP/GLP-1 agonist)
- Discuss indications for novel weight loss therapies and their cardiac implications
- Explain strategies to overcome barriers to medication access
CE certificate available upon successful completion of the post-test and program evaluation.
DNP, FNP-C, FAANP, FOMA
Accreditation:
PCNA is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030602.
